Weiwei Hu

机构：China Pharmaceutical University, Wuxi Taihu Hospital · ORCID：0000-0001-6916-3746

发表论文 42 篇 · 总被引 773 次 · h-index 16

代表论文

• PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity (2020 · Hepatology · 被引 92)
• Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction (2023 · Journal of Medicinal Chemistry · 被引 44)
• Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance (2019 · Bioorganic Chemistry · 被引 30)
• Effect of chronic stress on tumorigenesis and development (2022 · Cellular and Molecular Life Sciences · 被引 27)
• Correlation between resistin gene polymorphism and clinical aspects of lung cancer (2017 · Medicine · 被引 24)
• Stress-induced epinephrine promotes hepatocellular carcinoma progression via the USP10-PLAGL2 signaling loop (2024 · Experimental & Molecular Medicine · 被引 20)